17/B, Mahal Industrial Estate, Mahakali Caves Road. Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 5645 5645 Fax.: (91-22) 5645 5685



PRESS RELEASE

Sun Pharma Board to meet Jan 30: Q3 results

Jan 17, 2006, Mumbai: The Board of Directors of the speciality pharma company Sun Pharma will meet on the evening of Monday, January 30 to take on record the unaudited financial results for the third quarter ended 31th December, 2005.

Mr. Dilip Shanghvi, Chairman and Managing Director and Mr Sudhir Valia, Wholetime Director will conduct an hour long conference call to discuss the company's performance and take questions. This has been scheduled for the morning of Tuesday, January 31 at 9 am.

To participate, please dial the numbers listed below 5 to 10 min before the scheduled start time. The operator will provide instructions on asking questions. As the participation in the call is limited to 70 ports, early registration is suggested.

A replay would also be available two hours after the call at the numbers mentioned below, for three days. The transcript of the call will be posted on www.sunpharma.com.

Details of the numbers to be called:

Mumbai, Toll 9 am IST, January 31,2006	Primary Access: (+91 22) 2781 2277 Secondary Access: (+91 22) 5591 7977
Playback, Toll Till February 3 ,2006	Primary Access: (+91 22) 2788 0506 Secondary Access: (+91 22) 5591 7979

About Sun Pharma

Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is ranked 6th among all Indian pharma companies with a 3.27 % market share (ORG-IMS Stockist Secondary Audit, November 2005). In the Indian market, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics, with a rank among the top 3 companies (CMARC July - October 2005). More information about the company can be found at www.sunpharma.com.

Contact

Uday Baldota

Tel: +91 22 5645 5645, Ext 225

E mail: uday.baldota@sunpharma.com

Mira Desai

Tel: +91 22 5645 5645, Ext 184 E mail: miradesai@sunpharma.com,

corpcomm@sunpharma.com